Award
National Cancer Institute 11365092
Enhancing the Efficacy of Docetaxel in Prostate Cancer
Recipient
Beth Israel Deaconess Medical Center
Award Amount
$654,537.00
Ceiling
$654,537.00
Awarded
July 28, 2026
Identifier
11365092
NIH grant awarded to Beth Israel Deaconess Medical Center for research to improve docetaxel efficacy in prostate cancer, focusing on molecular and clinical studies to develop new therapeutic strategies.
Description
This is a NIH grant project focused on improving the efficacy of docetaxel in prostate cancer. The project involves molecular and clinical research, including biomarker identification and resistance mechanisms. The project is funded by the National Cancer Institute (NCI), part of NIH. The project aims to develop new therapeutic strategies to increase response and survival in metastatic castration-resistant prostate cancer.